ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) Quick Ratio
- Quick ratio · latest quarter: Value 2.46×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 2.46× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $393.71M ÷ $160.34M ≈ 2.46× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 393.71M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 160.34M USD | Liabilities, Current |
| Cash and equivalents | 34.12M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 204.43M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | 155.16M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 38.88M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $393.71M | $160.34M | $34.12M | $204.43M | $155.16M | $38.88M | 2.46× |
| 2026-03-31 | $368.38M | $163.20M | $34.76M | $189.24M | $144.38M | $37.39M | 2.26× |
| 2025-12-31 | $367.21M | $129.84M | $42.91M | $178.07M | $146.23M | $22.63M | 2.83× |
| 2025-09-30 | $306.18M | $99.77M | $47.12M | $143.95M | $115.12M | $22.42M | 3.07× |
| 2025-06-30 | $297.51M | $103.94M | $72.74M | $118.08M | $106.69M | $16.32M | 2.86× |
| 2025-03-31 | $283.50M | $91.13M | $53.10M | $144.98M | $85.42M | $16.61M | 3.11× |
| 2024-12-31 | $301.02M | $81.01M | $71.33M | $156.62M | $73.07M | $14.53M | 3.72× |
| 2024-09-30 | $390.68M | $172.43M | $134.85M | $195.71M | $60.12M | $14.02M | 2.27× |
| 2024-06-30 | $405.85M | $51.35M | $84.27M | $278.17M | $43.41M | $13.88M | 7.90× |
| 2024-03-31 | $441.02M | $47.31M | $190.10M | $213.77M | $37.15M | $13.25M | 9.32× |
| 2023-12-31 | $297.67M | $46.67M | $88.39M | $183.46M | $25.81M | $13.13M | 6.38× |
| 2023-09-30 | $246.53M | $41.89M | $107.47M | $119.64M | $19.42M | $13.91M | 5.89× |
| 2023-06-30 | $285.88M | $36.66M | $105.11M | $163.56M | $17.21M | $10.47M | 7.80× |
| 2023-03-31 | $345.17M | $37.02M | $81.41M | $251.00M | $12.77M | $8.55M | 9.32× |
| 2022-12-31 | $418.05M | $37.81M | $53.64M | $355.95M | $8.46M | $7.51M | 11.06× |
| 2022-09-30 | $479.39M | $37.10M | $81.54M | $395.42M | $2.43M | $4.31M | 12.92× |
| 2022-06-30 | (m) | $27.48M | $61.51M | $220.66M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $32.96M | $69.80M | $273.81M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $33.33M | $96.45M | $290.61M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $19.06M | $51.78M | $315.49M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $13.35M | $89.13M | $320.24M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $15.31M | $288.69M | $156.24M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $22.60M | $65.08M | $219.36M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $21.15M | $45.71M | $144.00M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $19.28M | $171.55M | $52.43M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $12.22M | $190.89M | $58.43M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $5.24M | $63.34M | $37.93M | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |